ArticleTranslational lung cancer research2026
Adjuvant therapy after pathological complete response in patients with non-small cell lung cancer: a multicenter retrospective cohort study.
Article in Translational lung cancer research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: In patients with resectable non-small cell lung cancer (NSCLC), the use of immune checkpoint inhibitors in both the neoadjuvant and perioperative settings has been associated with significant survival benefits. However, the comparative efficacy of neoadjuvant versus perioperative therapy remains unclear, particularly among patients who achieve pathological complete response (pCR). This study investigated the role of postoperative adjuvant therapy in patients with NSCLC achieving pCR after neoadjuvant therapy. Methods: In this retrospective multicenter study, patients with clinical stage II-IIIB NSCLC who achieved pCR following neoadjuvant therapy between 2019 and 2024 were identified. To balance baseline covariates between the two groups, inverse probability of treatment weighting was employed for patients who did and did not receive adjuvant therapy. Disease-free survival (DFS) and overall survival (OS) were subsequently compared between the two groups, with subgroup analyses conducted according to pathological type and clinical stage. Results: A total of 186 patients were included, with 135 receiving adjuvant therapy and 51 undergoing observation alone. After a median follow-up of 33 months and adjustment via inverse probability of treatment weighting, no significant differences in DFS or OS were observed between the adjuvant therapy group and the observation cohort. Specifically, the comparison of DFS yielded a log-rank P value of 0.818 [hazard ratio (HR) =1.17; 95% confidence interval (CI): 0.31-4.37], and the comparison of OS yielded a log-rank P value of 0.705 (HR =1.37; 95% CI: 0.26-7.14). Treatment-related adverse events occurred in 18 patients receiving adjuvant therapy, leading to discontinuation in 10 cases. Conclusions: In this multicenter real-world cohort, postoperative adjuvant therapy was not associated with improved DFS or OS among patients achieving pCR after neoadjuvant therapy. Given the limited number of events and wide CIs, these findings should be interpreted as exploratory and further validated in prospective studies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.